Biocon Ltd on Wednesday reported a 57.3 per cent decline in consolidated net profit to ₹56.7 crore in the September quarter of FY27.
The company had posted a consolidated net profit of ₹132.8 crore in the corresponding period of the preceding fiscal year, Biocon Ltd said in a regulatory filing.
Total income during the quarter rose to ₹4,423.4 crore, compared to ₹4,388.5 crore in the year-ago period, it added.
Total expenses in the quarter under review stood higher at ₹4,361.9 crore, against ₹4,205.3 crore in the same period a year ago, the company said.
Commenting on the performance, Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw said, “Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway. This represents an important milestone for biosimilar innovation and patient access.”
“This quarter we continued to make significant progress on our strategic priorities, laying the foundation for a stronger second half of FY27.
“Together with the upcoming European launch of Pertuzumab, expanded insulin manufacturing capacity in Malaysia to support growing US demand, and the strong early momentum of Yesafili and Yesintek in the US, we are well positioned for growth in the second half of FY27,” Shreehas Tambe, CEO & Managing Director, Biocon Ltd, said.
Shares of Biocon Ltd settled 0.19 per cent higher at ₹344 apiece on the BSE.
Published on November 4, 2026
